THE APEX TIMES
Northrop Grumman board declares quarterly dividend of $2.47 per share
The Falls Church-based defense contractor said its board approved a quarterly cash dividend for common shareholders, continuing a regular payout pattern for the company’s investors.
Northrop Grumman Corporation declared a quarterly dividend of $2.47 per share on its common stock, according to a notice published Aug. 19, 2026. The company said the board of directors approved the payment, indicating continued capital returns to shareholders alongside its ongoing defense and aerospace programs.
The announcement, distributed by Globe Newswire and carried by Yahoo Finance, provided the dividend per-share amount but did not, in the posted summary, specify additional terms such as the payment date or the record date that determines which shareholders receive the cash payout.
Northrop Grumman’s dividend is part of a broader pattern in the defense sector, where large, long-cycle contractors often balance heavy research, production, and systems work with shareholder distributions. For investors, a declared quarterly dividend can be viewed as one gauge of management’s comfort with cash flow over time, even as program schedules and government budgets can shift.
The company trades on the New York Stock Exchange under the ticker NOC. In its latest dividend announcement, the board action was described at the per-share level, reflecting how dividends are typically set for common stock rather than as a percentage of earnings.
While the post confirmed the dividend amount, it did not include any accompanying guidance about future payouts or changes to its dividend policy. It also did not describe whether the dividend level represents an increase, a hold, or a reduction versus prior quarters.
For Northrop Grumman, shareholder dividends are usually considered alongside other uses of cash that can include share repurchases, capital expenditures, and ongoing commitments tied to backlog execution. Those competing demands can influence whether boards adjust dividend levels, particularly in years with major program ramp-ups or investment cycles.
What to watch next is whether the company provides more complete dividend terms in subsequent filings or investor communications, including the record date and payable date, and whether management addresses capital return plans in its next earnings materials.
Investors may also look for consistency in future dividend declarations from Northrop Grumman, since the posted announcement focused narrowly on the approved per-share dividend without expanding on the rationale or outlook.
Why It Matters
- A declared quarterly dividend can be a announcement of management’s confidence in maintaining cash distributions through changing program and budget cycles.
- For defense-sector investors, dividend actions are often tracked alongside backlog execution and contract awards as a measure of financial stability.
- Because the announcement did not include record and payment dates in the republished summary, investors may need to consult the full corporate or regulatory communication to know when the payout will occur.
- Future investor focus is likely to include whether the dividend continues at the same level quarter to quarter, or whether management adjusts it alongside capital return priorities.
Sources
Key Facts
- Northrop Grumman’s board declared a quarterly dividend of $2.47 per share on its common stock.
- The announcement was published on Aug. 19, 2026.
- The company described the action as a board declaration for common shareholders.
- The dividend notice was distributed via Globe Newswire and republished by Yahoo Finance.
- Northrop Grumman’s common stock trades on the NYSE under the ticker NOC.
- The posted summary did not include the record date or payable date.
Defense Related
Yahoo Finance poses a long-horizon test: $1,000 in 2015 across NVIDIA, Apple and Bitcoin
A new comparison piece revisits three very different assets with the same starting bet: what $1,000 might have turned into over roughly 11 years.
Berkshire’s buyback pace accelerates under Greg Abel, according to a new filing cited by market reports
A report says Berkshire Hathaway has been buying back its shares at a much faster rate than in the prior quarter, and that the latest filing attributes the decision to CEO Greg Abel rather than to Warren Buffett.
JPMorgan Chase shares fall even as broader markets rise, ending near $357
JPM closed at $357.26 on the latest trading day, down 1.65% from its prior close, according to Yahoo Finance. The move contrasts with the day’s market gains reported in the same update.
Moderna and Merck lift big-biopharma sentiment as Treasury yields ease; S&P 500 and Nasdaq edge higher
U.S. stock index futures pointed to modest gains as Treasury yields moved lower Wednesday. In biotechnology and large drugmakers, Moderna and Merck were among the names drawing notable attention.
Bank of America turns bullish on Medtronic ahead of earnings, citing a second catalyst building
A market note tied Bank of America’s outlook to Medtronic’s still-strong near-term momentum, while pointing to another potential driver developing into a later date.
Tesla’s “Model Y L” heads to the U.S., but investors are asking whether it can restart growth
A widely discussed new Model Y variant, dubbed “Model Y L,” is being framed as a bid to reach customers Tesla is currently missing.
Eli Lilly and Novo Nordisk face a new test in the shift from injectable to oral GLP-1 drugs, Yahoo Finance asks
The next phase of the weight-loss and diabetes drug rivalry could hinge less on injections and more on whether either company can deliver effective oral GLP-1 therapies at scale.
Moderna stock surges after report of success in melanoma vaccine trial
Moderna shares rose sharply following a media report highlighting encouraging results from a melanoma vaccine study, with commentators calling the work a potential step toward a breakthrough in cancer therapy.
Moderna-linked cancer vaccine catalyst lifts shares as BioNTech rally fades in traders’ view
A sharp move higher in BioNTech shares followed a Moderna cancer vaccine development, but analysts at Leerink questioned whether the price momentum is likely to last.
Moderna’s Intismeran posts melanoma recurrence win, strengthening the turnaround case for mRNA oncology
Moderna said its personalized mRNA cancer vaccine Intismeran met its main goal in a melanoma study, a development investors are watching closely as the company resets expectations for its oncology pipeline.